
Arcutis Biotherapeutics, Inc.: shareholders and insiders
Price
$27.61
November 18, 2026Market cap $3.4B
What Ploutos Investor adds for Arcutis Biotherapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
Insiders and their shares
Purchases and sales by officers and directors, from their own Form 4 filings.
Reading the newest filings from the SEC. This part fills in on its own in a few seconds.
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- BlackRock, Inc.Share of class14.1%
- Frazier Life Sciences VIII, L.P.with 14 more personsShare of class7.50%
- Rubric Capital Management LPwith 1 more personShare of class6.75%
- State StreetShare of class6.10%
- Polar Capital Holdings Plcwith 1 more personShare of class5.28%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14.1% | 17.75M | Oct 5, 2026 | 13G/A | |
| Frazier Life Sciences VIII, L.P.with 14 more persons | 7.50% | 8.94M | Aug 20, 2025 | 13D/A | |
| Rubric Capital Management LPwith 1 more person | 6.75% | 8.27M | Feb 13, 2026 | 13G/A | |
| State Street | 6.10% | 7.72M | Nov 10, 20263 filings since May 12, 2026 | 13G | |
| Polar Capital Holdings Plcwith 1 more person | 5.28% | 6.61M | Aug 14, 20263 filings since May 15, 2025 | 13G |
What the holders on a 13D state as their purpose
From Item 4 of the filing, in the holder's own words. It is the intention the holder states, not something that happened.
Frazier Life Sciences VIII, L.P.7.5%From the filing of Aug 20, 2025
FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII each acquired the FLS VIII Shares (as defined below), the FHM Life Sciences VIII, L.L.C. Shares (as defined below), the FLS X Shares (as defined below), the FLSPF Shares (as defined below), the FLSPOF Shares (as defined below), the FLS XI Shares (as defined below) and the FLS XII Shares (as defined below), as the case me be, for investment purposes. Depending on market conditions, its continuing evaluation of the business and prospects of the Issuer and other factors, FLS VIII, FHM Life Sciences VIII, L.L.C, FLS X, FLSPF, FLSPOF, FLS XI and FLS XII and other Reporting Persons may dispose of or acquire…
From the filing of Aug 20, 2025
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- D.E. ShawIn the quarter-33%
- Citadel Advisors (Griffin)In the quarter+32%
- Millennium Mgmt (Englander)In the quarter+63%
- Renaissance TechnologiesIn the quarter+715%
- Point72 (Cohen)In the quarter
- AQR CapitalIn the quarter+52%
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| D.E. Shaw | 2.65M | -33% | $70M | 0.04% |
| Citadel Advisors (Griffin) | 1.53M | +32% | $41M | 0.02% |
| Millennium Mgmt (Englander) | 919.4K | +63% | $24M | 0.02% |
| Renaissance Technologies | 476.1K | +715% | $13M | 0.02% |
| Point72 (Cohen) | – | – | 0.01% | |
| AQR Capital | 502.4K | +52% | $13M | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 16.5% of its shares outstanding were held short, -5.5% since the report before.
- Shares held short
- 20.49M
- 16.5%
- Since the report before21.69M on Sep 30, 2026
- -5.5%
- 9.8
- 2.10M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 90%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 17.07M
- Nov 15, 2023: Shares held short 17.51M
- Nov 30, 2023: Shares held short 20.90M
- Dec 15, 2023: Shares held short 19.46M
- Dec 29, 2023: Shares held short 20.18M
- Jan 12, 2024: Shares held short 20.83M
- Jan 31, 2024: Shares held short 16.78M
- Feb 15, 2024: Shares held short 16.94M
- Feb 29, 2024: Shares held short 15.78M
- Mar 15, 2024: Shares held short 14.99M
- Mar 28, 2024: Shares held short 19.26M
- Apr 15, 2024: Shares held short 19.66M
- Apr 30, 2024: Shares held short 21.69M
- May 15, 2024: Shares held short 22.17M
- May 31, 2024: Shares held short 24.64M
- Jun 14, 2024: Shares held short 26.02M
- Jun 28, 2024: Shares held short 21.34M
- Jul 15, 2024: Shares held short 22.66M
- Jul 31, 2024: Shares held short 21.95M
- Aug 15, 2024: Shares held short 23.80M
- Aug 30, 2024: Shares held short 24.68M
- Sep 13, 2024: Shares held short 24.86M
- Sep 30, 2024: Shares held short 27.13M
- Oct 15, 2024: Shares held short 28.06M
- Oct 31, 2024: Shares held short 27.76M
- Nov 15, 2024: Shares held short 25.02M
- Nov 29, 2024: Shares held short 23.53M
- Dec 13, 2024: Shares held short 23.11M
- Dec 31, 2024: Shares held short 20.97M
- Jan 15, 2025: Shares held short 20.22M
- Jan 31, 2025: Shares held short 18.91M
- Feb 14, 2025: Shares held short 17.64M
- Feb 28, 2025: Shares held short 19.77M
- Mar 14, 2025: Shares held short 15.11M
- Mar 31, 2025: Shares held short 14.63M
- Apr 15, 2025: Shares held short 14.38M
- Apr 30, 2025: Shares held short 15.14M
- May 15, 2025: Shares held short 16.04M
- May 30, 2025: Shares held short 16.78M
- Jun 13, 2025: Shares held short 18.64M
- Jun 30, 2025: Shares held short 20.60M
- Jul 15, 2025: Shares held short 17.27M
- Jul 31, 2025: Shares held short 16.64M
- Aug 15, 2025: Shares held short 18.40M
- Aug 29, 2025: Shares held short 17.02M
- Sep 15, 2025: Shares held short 16.05M
- Sep 30, 2025: Shares held short 14.45M
- Oct 15, 2025: Shares held short 14.28M
- Oct 31, 2025: Shares held short 13.48M
- Nov 14, 2025: Shares held short 13.72M
- Nov 28, 2025: Shares held short 12.06M
- Dec 15, 2025: Shares held short 13.24M
- Dec 31, 2025: Shares held short 15.01M
- Jan 15, 2026: Shares held short 15.22M
- Jan 30, 2026: Shares held short 16.01M
- Feb 13, 2026: Shares held short 16.38M
- Feb 27, 2026: Shares held short 15.29M
- Mar 13, 2026: Shares held short 15.75M
- Mar 31, 2026: Shares held short 16.80M
- Apr 15, 2026: Shares held short 16.58M
- Apr 30, 2026: Shares held short 16.88M
- May 15, 2026: Shares held short 17.55M
- May 29, 2026: Shares held short 16.23M
- Jun 15, 2026: Shares held short 15.82M
- Jun 30, 2026: Shares held short 14.02M
- Jul 15, 2026: Shares held short 13.56M
- Jul 31, 2026: Shares held short 12.69M
- Aug 14, 2026: Shares held short 14.72M
- Aug 31, 2026: Shares held short 16.56M
- Sep 15, 2026: Shares held short 18.46M
- Sep 30, 2026: Shares held short 21.69M
- Oct 15, 2026: Shares held short 20.49M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading67.4% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 67.4% of the shares in the reported trades were short sales, against 49.2% in the 14 before.
- Last 14 sessionsOct 30, 2026 – Nov 18, 2026
- 67.4%
- The 14 beforeOct 12, 2026 – Oct 29, 2026
- 49.2%
- Change
- +18.2 pts
- Short sales a dayon average, of 842.7K shares
- 568.3K
- More than atof 3,656 US-listed companies, same days
- 95%
- Median of alleight in ten from 34.4% to 63.7%
- 50.3%
- Short sales
- Oct 12, 2026: Short sales 68.6%
- Oct 13, 2026: Short sales 65.5%
- Oct 14, 2026: Short sales 56.6%
- Oct 15, 2026: Short sales 57.9%
- Oct 16, 2026: Short sales 66.9%
- Oct 19, 2026: Short sales 47.1%
- Oct 20, 2026: Short sales 41.6%
- Oct 21, 2026: Short sales 49.6%
- Oct 22, 2026: Short sales 32.7%
- Oct 23, 2026: Short sales 41.8%
- Oct 26, 2026: Short sales 46.5%
- Oct 27, 2026: Short sales 26.7%
- Oct 28, 2026: Short sales 58.9%
- Oct 29, 2026: Short sales 50.8%
- Oct 30, 2026: Short sales 74.6%
- Nov 2, 2026: Short sales 70.5%
- Nov 3, 2026: Short sales 64.9%
- Nov 4, 2026: Short sales 54.7%
- Nov 5, 2026: Short sales 61.9%
- Nov 6, 2026: Short sales 65.5%
- Nov 9, 2026: Short sales 66.6%
- Nov 10, 2026: Short sales 79.9%
- Nov 11, 2026: Short sales 79.8%
- Nov 12, 2026: Short sales 73.8%
- Nov 13, 2026: Short sales 70.8%
- Nov 16, 2026: Short sales 75.4%
- Nov 17, 2026: Short sales 61.1%
- Nov 18, 2026: Short sales 54.4%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
The ETFs that hold it
Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- XBIState Street(R) SPDR(R) S&P(R) Biotech ETFWeight in the fund0.71%
- LABUDirexion Daily S&P Biotech Bull 3X SharesWeight in the fund0.54%
- IBBiShares Biotechnology ETFWeight in the fund0.23%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.18%
- FESMFidelity Enhanced Small Cap Core ETFWeight in the fund0.12%
- IWMiShares Russell 2000 ETFWeight in the fund0.09%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.09%
- SCHASchwab U.S. Small-Cap ETFWeight in the fund0.06%
- VHTVanguard Health Care Index FundWeight in the fund0.04%
- VXFVanguard Extended Market Index FundWeight in the fund0.04%
15 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 240
- Q4 2025: Managers 283
- Q1 2026: Managers 273
- Q2 2026: Managers 272
Institutional investors by quarter
The fund managers holding ARQT, quarter by quarter, from Q1 2020 to Q2 2025, 22 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 272 managers held 131M shares, worth $3.4B. During the quarter 41 opened a position, 42 closed one, 93 added and 99 trimmed.
The largest holders, Q2 2026
- Montanova CapitalIn the quarter+0.9%
- BlackRockIn the quarter+15%
- Frazier Life Sciences ManagementIn the quarter
- Rubric Capital ManagementIn the quarter
- Polar Capital HoldingsIn the quarter+17%
- State StreetIn the quarter-7.5%
- Vanguard Capital ManagementIn the quarter+2.4%
- Morgan StanleyIn the quarter+5.5%
- Jennison AssociatesIn the quarter-15%
- D.E. ShawIn the quarter+58%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Montanova Capital | 12.44M | +0.9% | $326M |
| BlackRock | 10.55M | +15% | $277M |
| Frazier Life Sciences Management | 9.87M | $259M | |
| Rubric Capital Management | 8.27M | $217M | |
| Polar Capital Holdings | 6.61M | +17% | $173M |
| State Street | 5.82M | -7.5% | $153M |
| Vanguard Capital Management | 4.99M | +2.4% | $131M |
| Morgan Stanley | 4.45M | +5.5% | $117M |
| Jennison Associates | 4.22M | -15% | $111M |
| D.E. Shaw | 3.95M | +58% | $104M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Arcutis Biotherapeutics's filings show?
Who buys and sells is one part of Arcutis Biotherapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Which well-known managers hold ARQT?
6 of the managers we track held the shares on Sep 30, 2026. The largest position was D.E. Shaw's, worth $70M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.